Cargando…

Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study

OBJECTIVE: To investigate the risk of immune-mediated inflammatory diseases (IMIDs) in patients with ankylosing spondylitis (AS). METHODS: Using 2003–2012 claims data from the Taiwanese National Health Insurance Research Database, we identified 30,911 newly diagnosed AS patients requiring medical th...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hsin-Hua, Chao, Wen-Cheng, Chen, Yi-Hsing, Hsieh, Tsu-Yi, Lai, Kuo-Lung, Chen, Yi-Ming, Hung, Wei-Ting, Lin, Ching-Tsai, Tseng, Chih-Wei, Lin, Ching-Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716905/
https://www.ncbi.nlm.nih.gov/pubmed/31464632
http://dx.doi.org/10.1186/s13075-019-1980-1
_version_ 1783447466681565184
author Chen, Hsin-Hua
Chao, Wen-Cheng
Chen, Yi-Hsing
Hsieh, Tsu-Yi
Lai, Kuo-Lung
Chen, Yi-Ming
Hung, Wei-Ting
Lin, Ching-Tsai
Tseng, Chih-Wei
Lin, Ching-Heng
author_facet Chen, Hsin-Hua
Chao, Wen-Cheng
Chen, Yi-Hsing
Hsieh, Tsu-Yi
Lai, Kuo-Lung
Chen, Yi-Ming
Hung, Wei-Ting
Lin, Ching-Tsai
Tseng, Chih-Wei
Lin, Ching-Heng
author_sort Chen, Hsin-Hua
collection PubMed
description OBJECTIVE: To investigate the risk of immune-mediated inflammatory diseases (IMIDs) in patients with ankylosing spondylitis (AS). METHODS: Using 2003–2012 claims data from the Taiwanese National Health Insurance Research Database, we identified 30,911 newly diagnosed AS patients requiring medical therapy from 2006 to 2012. In addition, we randomly selected 309,110 non-AS individuals matching (1:10) the AS patients with regard to age, sex and the year of the index date. After excluding subjects with the corresponding prior IMIDs, we calculated the incidence rates (IRs) of various IMIDs in the AS and non-AS cohorts and estimated the hazard ratios (HRs) with 95% confidence intervals after adjusting for age, sex, the Charlson comorbidity index, the frequency of ambulatory visits during the follow-up period and medications. We conducted sensitivity analyses by excluding those who developed IMIDs within 3 months after the index date. RESULTS: In the follow-up period, we found that newly diagnosed AS patients had significantly increased risks of acute anterior uveitis, psoriasis, Sjögren’s syndrome, thromboangiitis obliterans, Behcet’s disease and sarcoidosis. However, the risk of Sjögren’s syndrome did not increase in AS patients in the sensitivity analysis. In the same period, this study found no significant differences in the risks of Crohn’s disease, ulcerative colitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, pemphigus and vitiligo between newly diagnosed AS patients and non-AS individuals. AS patients had a significantly reduced risk of rheumatoid arthritis. CONCLUSION: Newly diagnosed Taiwanese AS patients had increased risks of acute anterior uveitis, psoriasis, thromboangiitis obliterans, Behcet’s disease and sarcoidosis, but a reduced risk of rheumatoid arthritis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13075-019-1980-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6716905
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67169052019-09-04 Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study Chen, Hsin-Hua Chao, Wen-Cheng Chen, Yi-Hsing Hsieh, Tsu-Yi Lai, Kuo-Lung Chen, Yi-Ming Hung, Wei-Ting Lin, Ching-Tsai Tseng, Chih-Wei Lin, Ching-Heng Arthritis Res Ther Research Article OBJECTIVE: To investigate the risk of immune-mediated inflammatory diseases (IMIDs) in patients with ankylosing spondylitis (AS). METHODS: Using 2003–2012 claims data from the Taiwanese National Health Insurance Research Database, we identified 30,911 newly diagnosed AS patients requiring medical therapy from 2006 to 2012. In addition, we randomly selected 309,110 non-AS individuals matching (1:10) the AS patients with regard to age, sex and the year of the index date. After excluding subjects with the corresponding prior IMIDs, we calculated the incidence rates (IRs) of various IMIDs in the AS and non-AS cohorts and estimated the hazard ratios (HRs) with 95% confidence intervals after adjusting for age, sex, the Charlson comorbidity index, the frequency of ambulatory visits during the follow-up period and medications. We conducted sensitivity analyses by excluding those who developed IMIDs within 3 months after the index date. RESULTS: In the follow-up period, we found that newly diagnosed AS patients had significantly increased risks of acute anterior uveitis, psoriasis, Sjögren’s syndrome, thromboangiitis obliterans, Behcet’s disease and sarcoidosis. However, the risk of Sjögren’s syndrome did not increase in AS patients in the sensitivity analysis. In the same period, this study found no significant differences in the risks of Crohn’s disease, ulcerative colitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, pemphigus and vitiligo between newly diagnosed AS patients and non-AS individuals. AS patients had a significantly reduced risk of rheumatoid arthritis. CONCLUSION: Newly diagnosed Taiwanese AS patients had increased risks of acute anterior uveitis, psoriasis, thromboangiitis obliterans, Behcet’s disease and sarcoidosis, but a reduced risk of rheumatoid arthritis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13075-019-1980-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-29 2019 /pmc/articles/PMC6716905/ /pubmed/31464632 http://dx.doi.org/10.1186/s13075-019-1980-1 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Chen, Hsin-Hua
Chao, Wen-Cheng
Chen, Yi-Hsing
Hsieh, Tsu-Yi
Lai, Kuo-Lung
Chen, Yi-Ming
Hung, Wei-Ting
Lin, Ching-Tsai
Tseng, Chih-Wei
Lin, Ching-Heng
Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study
title Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study
title_full Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study
title_fullStr Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study
title_full_unstemmed Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study
title_short Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study
title_sort risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716905/
https://www.ncbi.nlm.nih.gov/pubmed/31464632
http://dx.doi.org/10.1186/s13075-019-1980-1
work_keys_str_mv AT chenhsinhua riskofimmunemediatedinflammatorydiseasesinnewlydiagnosedankylosingspondylitispatientsapopulationbasedmatchedcohortstudy
AT chaowencheng riskofimmunemediatedinflammatorydiseasesinnewlydiagnosedankylosingspondylitispatientsapopulationbasedmatchedcohortstudy
AT chenyihsing riskofimmunemediatedinflammatorydiseasesinnewlydiagnosedankylosingspondylitispatientsapopulationbasedmatchedcohortstudy
AT hsiehtsuyi riskofimmunemediatedinflammatorydiseasesinnewlydiagnosedankylosingspondylitispatientsapopulationbasedmatchedcohortstudy
AT laikuolung riskofimmunemediatedinflammatorydiseasesinnewlydiagnosedankylosingspondylitispatientsapopulationbasedmatchedcohortstudy
AT chenyiming riskofimmunemediatedinflammatorydiseasesinnewlydiagnosedankylosingspondylitispatientsapopulationbasedmatchedcohortstudy
AT hungweiting riskofimmunemediatedinflammatorydiseasesinnewlydiagnosedankylosingspondylitispatientsapopulationbasedmatchedcohortstudy
AT linchingtsai riskofimmunemediatedinflammatorydiseasesinnewlydiagnosedankylosingspondylitispatientsapopulationbasedmatchedcohortstudy
AT tsengchihwei riskofimmunemediatedinflammatorydiseasesinnewlydiagnosedankylosingspondylitispatientsapopulationbasedmatchedcohortstudy
AT linchingheng riskofimmunemediatedinflammatorydiseasesinnewlydiagnosedankylosingspondylitispatientsapopulationbasedmatchedcohortstudy